![]() |
|
|
Forward to a colleague |
||
Access Full Stories Pfizer revealed today that it is abandoning its once-touted blockbuster Exubera, ending months of speculation as to whether the fledging world-first inhalable insulin would sink or swim in the fierce waters of... Read Novartis suffers from generics, cuts jobs Novartis has turned in its results for the first nine months of the year, with income gnawed at by generic competition and product suspensions, but still claiming record earnings helped along by divestment gains... Read Industry bodies call for EU clinical trials directive changes Two major bioscience industry trade associations have called for changes to be made to the European clinical trials directive in order to bring about "harmonisation, transparency and consistency" in this area across... Read Big players boosting 3PL clout Three big industry names have been busily bolstering their pharma logistics clout: Thermo Fisher Scientific, UPS and Kuehne+Nagel... Read Online drug discovery services database to be launched A US start-up firm is gearing up to launch an online database where researchers can access a variety of drug discovery service providers across the globe... Read |
|||||||||
All News Headlines for: October | September | August |
|||||||||
|
Related Industry News Fingerprinting the structure of pharmaceuticals A new solid-state proton NMR (nuclear magnetic resonance) technique has been developed that can quickly determine polymorphism of active pharmaceuticals within tablet formulations... Read Wyeth ups the ante with new proteomics method Researchers from Wyeth Research's Biological Technologies division have described how the use of a titania-affinity enrichment step can aid in the discovery of post-translational protein modifications... Read Tracking HIV evolution from birth to death A group of US researchers have tracked how HIV evolves over the course of a person's lifetime and the findings could pave the way for new drugs that combat the disease before it can kill... Read Billionaire 'raider' circles as Biogen put up for sale Biogen Idec has announced it is seeking a buyer for the company and has already received several expressions of interest - including a reputed $23bn (€16.2bn) bid from billionaire corporate raider Carl Icahn... Read
|
|||||||||
|
|||||
Forward to a colleague |
|||||
To continue to receive this newsletter in your inbox, please add newsletter@OutSourcing-Pharma.com to your address book |
||
Update preferences | Change your email address | Unsubscribe |
||
Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback |
||
| © 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com |
||